Spruce Biosciences Inc. (SPRB) - Long-Term Debt to Capital Coefficient

The daily price chart for Spruce Biosciences (SPRB) helps assess the impact of ESG standards and environmental responsibility in the development of therapies for rare endocrine pathologies. The business relies on US centers for the development of treatments for adrenal hyperplasia, where the indicator is 0.06. The company's stability is based on successful clinical trials, innovation cost control, and the maintenance of a sufficient investment reserve.

Spruce Biosciences specializes in developing hormonal treatments for niche orphan markets. This indicator measures the share of long-term loans within the equity structure to determine the degree of financial leverage. For R&D companies, low leverage minimizes bankruptcy risks in the absence of revenue. The current value of 0.06 confirms the stability of a model that avoids plant expenditures. Analyzing the ratio of long-term liabilities to equity allows for an assessment of the balance between debt financing and capitalization.